Reyataz, Atazanavir Sulfate News

PITTSBURGH, Dec. 20, 2011 /PRNewswire/ -- Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral therapies used to treat HIV/AIDS under the World Health Organization's Prequalification of Medicines Programme.

Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS Mylan Inc.

Alvin Ailey American Dance Theater Premieres Home, A New Work Inspired by the Winning Photos and Essays from the 2011 REYATAZA "Fight HIV Your Way" Contest, an Initiative of Bristol-Myers Squibb Company PRINCETON, N.J. & NEW YORK-- --Bristol-Myers Squibb Company and Alvin Ailey American Dance Theater today announced the premiere of an original ... (more)

Following new data from study AI424-182 on pregnant women living with HIV, the European Commission approved a labeling update for Reyataz .

As pregnancy can reduce the serum levels of many ARVs, it is important to know the optimal dosage.